Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States – IVY Network, 18 States, December 26, 2021-August 31, 2022Article Published on 2022-10-212022-11-16 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, [키워드] accounted Against B.1.1.529 booster dose category COVID-19 vaccine dose Effectiveness eligible adult estimate expected Hospitalization Immunity immunocompetent adult immunogenic include Infection Interpretation Lineage lineages majority monovalent mRNA mRNA component mRNA COVID-19 vaccine mRNA vaccine network omicron overlapped Period predominant Prevent protection receive reduce replaced SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 strain second dose the United State vaccination Vaccine Vaccine-induced immunity variant waned [DOI] 10.15585/mmwr.mm7142a3 PMC 바로가기
Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019미국 수두 예방접종 프로그램 동안 심각한 수두 질환의 감소: 입원 및 사망, 1990-2019Article Published on 2022-10-212023-05-31 Journal: The Journal of Infectious Diseases [Category] 대상포진, 두창, 수두, 홍역, [키워드] death Hospitalization Impact Mortality Program Vaccine varicella VZV [DOI] 10.1093/infdis/jiac242
Delayed encephalopathy after COVID-19: A case series of six patientsArticle Published on 2022-10-212022-11-15 Journal: Medicine [Category] 진단, [키워드] absence accompanied acute respiratory syndrome Administered age autoantibody case sery cerebrospinal fluid characterized Computed tomography contribute coronavirus coronavirus disease COVID-19 CSF Delayed demonstrated disturbance of consciousness Duration dysfunction electroencephalogram elevated Encephalopathy evaluated female Hospitalization Immunoglobulin Immunotherapy interleukin-6 lacunar infarction magnetic resonance imaging males moderate MOST neurological Neurological deficit occur Pathogenesis Patient patients polymerase chain protein level pulse ranged remained Repeat resolved reverse transcription serum severity of COVID-19 Symptom Treatment with COVID-19 worsening [DOI] 10.1097/MD.0000000000031029 PMC 바로가기
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance – VISION Network, 10 States, December 2021-August 2022Article Published on 2022-10-212022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Against Analysis antibody antivirals B.1.1.529 benefit booster booster dose cause circulating Committee component conditions COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness eligible Hospitalization Hospitalized immunocompromising condition Mask moderate molecular test mRNA network nonpharmaceutical intervention offered omicron Person positive Practice predominant Prophylactic protection Protective receive recipient recommendation recommendations reduced Restricting SARS-CoV-2 therapy vaccination Vaccine variant virus [DOI] 10.15585/mmwr.mm7142a4 PMC 바로가기
Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in childrenArticle Published on 2022-10-192022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome analyzed anti-S IgG antibody Antigen antigen specific antibody Asymptomatic cause children collected coronavirus cross-react cross-reactive cross-reactive antibody exhibit HCoV-OC43 Hospitalization Humoral immunity IgG antibody Infection low pathogenic human coronaviruses median age mild symptoms Mutant SARS-CoV-2 Neutralizing activity neutralizing antibody nucleocapsid occurred outbreak pathogenic pathogenic human coronavirus question Re-infection reached Receptor binding domain SARS-CoV-2 seropositive sample serum sample Seven SRAS-CoV-2 These data wild-type [DOI] 10.3389/fimmu.2022.1042406 PMC 바로가기
Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trialArticle Published on 2022-10-182022-11-15 Journal: Nature Communications [Category] 치료제, [키워드] 95% CI benefit confidence interval COVID-19 COVID-19 infection Effect Evidence fatigue Finnish Follow-up Hospitalization hospitalized patients hospitals joint long-COVID Long-term follow-up memory occurred outcome Pain Patient Primary outcome problem Quality of life Randomized randomized trial recruited Remdesivir reported resulting SOC Standard of care survived Symptom Symptoms Trial [DOI] 10.1038/s41467-022-33825-5 PMC 바로가기
Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2Article Published on 2022-10-172022-11-16 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Admission Against booster coronavirus coronavirus 2 COVID-19 Cox proportional hazard Czech Republic declined Delta Effectiveness evade Hospitalization Immunity Infection infections intensive care Logistic regression need for oxygen Odds ratio omicron Omicron variant outcome oxygen Postinfection postinfection immunity protection reached recent respiratory risk SARS-CoV-2 therapy vaccination Vaccine vaccine effectiveness variant [DOI] 10.1093/infdis/jiac161 PMC 바로가기
Accuracy of quality of life questionnaire as a diagnostic tool for SARS-CoV-2 pulmonary sequelaeArticle Published on 2022-10-142022-11-16 Journal: Medicina clínica [Category] COVID19(2023년), SARS, 치료기술, [키워드] age alteration alterations AUC Cardiopulmonary Covid persistente COVID-19 CPET Cuestionario de calidad de vida SF-12 detect diagnostic domain English female first positive follow-up study functional Healthcare system hospital discharge Hospitalization identify Long Long COVID maximum oxygen consumption media Patient PCR performed physical predicted primer Prospective prospectivo Prueba de esfuerzo cardiopulmonar Pruebas funcionales respiratorias pulmonary Pulmonary function Pulmonary function test Quality of life questionnaire reduced SARS-CoV-2 Sensitivity and specificity SF-12 quality of life questionnaire. significantly Spanish survivor Symptom Symptoms utility [DOI] 10.1016/j.medcli.2022.02.007 PMC 바로가기
Interplay between demographic, clinical and polygenic risk factors for severe COVID-19Article Published on 2022-10-132022-11-15 Journal: International Journal of Epidemiology [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] 95% CI adjusted odds ratio Admission age antiviral response association co-morbidity conducted COVID-19 COVID-19 diagnosis Critical care death develop diagnosed with COVID-19 enrolment Epidemiology European Factor Factors General population genetic data genetic risk factor Genetic variant greater highest hospital Hospitalization identify IMPROVE individual interquartile range lowest median men morbidity obesity outcomes participant Pathway analysis Pathways Patient polygenic risk score polymorphism PRS reported risk risk factor risk prediction severe COVID-19 single-nucleotide Smokers socio-demographic UK biobank was performed [DOI] 10.1093/ije/dyac137 PMC 바로가기
Effectiveness of the Fiocruz recombinant ChadOx1-nCoV19 against variants of SARS-CoV-2 in the Municipality of Botucatu-SPArticle Published on 2022-10-132022-11-16 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 변종, [키워드] “real world” study. Analysis Brazil calculated ChAdOx1 clinical trial comparable Control Coverage COVID-19 COVID-19 disease COVID-19 pandemic death Delta delta variant demographics dose Effectiveness Efficacy eligible first dose Gamma Hospitalization individual initiated Lineage material municipality offered PCR test PCR tests positive raise reduced reported sequenced severe disease severity state Strains Study design symptomatic infection Symptoms unique vaccinated individual vaccinated individuals vaccination Vaccine vaccine dose Vaccines variant variants of concern variants of SARS-CoV-2 [DOI] 10.3389/fpubh.2022.1016402 PMC 바로가기